Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitors and nutritional status in cancer patients
jRCT1031250819Active, not recruiting
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of empagliflozin, dapagliflozin and canagliflozin in cancer, type 2 diabetes mellitus (T2DM), heart failure (HF) and 1 more (2 arms), sponsored by none. Primary endpoint: Change in lean body mass. Started Mar 2026; status: active, not recruiting.
02
Drugs
empagliflozindapagliflozincanagliflozin
03
Conditions
cancertype 2 diabetes mellitus (T2DM)heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1031250819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250819.